Introduction
============

Globally, approximately 60 to 80 million couples are likely to be affected by infertility per year ([@B1]). About 15% of couples suffer from subfertility around the world ([@B2]). The rate of male and female infertility incidences have been estimated to be equal with each explaining approximately 35-40% of cases. The cause of infertility in the remaining proportion of cases (male or female) may be due to a combination of disorders in the two genders (20- 30%) ([@B3]), through which, 15-30% of cases are diagnosed as unexplained infertility ([@B4]).

The first step to achieve a successful pregnancy is embryo implantation which needs an intact embryo, an endometrium and the synchronization between them ([@B5]). Failure in implantation is multifactorial and may be due to embryonic or maternal dysfunction during the dialogue window between them. Coagulation, immunological, endothelial, endocrine and metabolic disorders are among the most common known causative factors of subfertility ([@B6], [@B7]).

Diabetes is a variety of metabolic diseases in which individuals are unable to produce or uptake adequate levels of insulin, resulting in high levels of blood glucose ([@B8]). Diabetes mellitus could deregulate a variety of cellular and molecular pathways ([@B9]).

A total of 425 million diabetic individuals have been reported worldwide in 2017 and it is estimated that this population will reach 629 million by 2045 ([@B10]). The incidence of type 2 diabetes (T2D) is also rising and is accompanied with age reduction in its onset, especially in women ([@B11]).

Diabetes can seriously affect the outcome of embryo implantation and pregnancy. It seems diabetes mellitus impairs the molecular functions of the female reproductive system and thus causes improper implantation and/or fetal loss ([@B12]).

Some reports have shown that miscarriage, neonatal morbidity and mortality, and neonatal congenital malformations are observed in women who suffer from T2D ([@B13], [@B14]).

Administration of metformin to T2D patients for blood glucose level reduction is common. Metformin affects cell insulin resistance, descends gluconeogenesis by liver and increases blood glucose utilization, therefore leading to euglycemia ([@B15]).

Pioglitazone is a member of the thiazolidinediones (TZDs) family, which is used as an antidiabetic drug. It acts by binding to peroxisome proliferator-activated receptor gamma (PPAR-γ). This drug therefore improves glycemic control by increasing insulin sensitivity at cellular level ([@B16]).

The association of subfertility or infertility with diabetes, as a metabolic disease, has been previously evaluated ([@B17]). However, the effect of diabetes on gene expression at the transcript and protein levels have not been evaluated during the implantation window ([@B14]).

The embryo-maternal crosstalk during the implantation window involves several genes which ought to be expressed at the right time either in the blastocyst or the endometrium ([@B18]). Receptivity of endometrium is the key point for implantation of the blastocyst ([@B18], [@B19]). This receptivity is provided by a number of molecules which which reach their peak values during the window of implantation ([@B5]). Some of these molecules include integrins, mucins, vascular endothelial growth factor (VEGF), and osteopontin ([@B20]). Integrin family members act as receptors for multiple ligands such as osteopontin, laminin and collagen.

In rats, *Opn* gene has 7 exons, and its location is on the 14p22) ([@B21]). Osteopontin (*Opn*) promotes cell adhesion and invasion through its Arg-Gly-Asp domain ([@B5]). *Opn* is shown to be present at a high level in the epithelial layer (during mid-secretary phase) in human, mouse and rabbit uterine ([@B22], [@B23]). Osteopontin has been also identified as a protein associated with metastatic cancers, as an extracellular matrix protein of bones and teeth, as a cytokine produced by activated lymphocytes and macrophages, and as a major constituent of the uterus and placenta during pregnancy ([@B22]).

Given the rise of T2D prevalence its effects on the female reproductive system, we quantified the expression of *Opn* in the endometrium of diabetic rat models to examine the association of *Opn* with T2D and evaluate the molecular effect of metformin and pioglitazone treatments on *Opn* expression.

Materials and Methods
=====================

Animal and maintenance
----------------------

This interventional and experimental study on diabetic rat models was conducted at the Central Laboratory of Isfahan University of Medical Sciences in 2017. This work has the Ethical Committee code number IR.MUI.REC.1394.1.184.

Adult virgin female Wistar rats weighting 200-250 g were obtained from Pasteur Institute of Iran, aged 6-8 weeks, maintained in conventional wire mesh cages at room temperature 21 ± 1°C and humidity of 45-50% with light/dark cycle. Rats had access to standard dry pellets and water.

Induction of diabetes
---------------------

Diabetes was induced in rats by injecting 60 mg/kg streptozotocin (STZ, Sigma-Aldrich Chemie, Germany) intraperitoneally. Fifteen minutes prior to STZ injection, 200-230 mg/kg nicotinamide (NA, Sigma-Aldrich Chemie, Germany) was injected intraperitoneally ([@B24]-[@B26]).

Blood samples were taken from the tail vein and glucose level values were measured using a glucometer (HemoCue Glucose 201+, Ängelholm, Sweden). Rats with blood glucose levels above 250 mg/dl were considered manifestly as diabetic ([@B27]).

Study design and tissue collection
----------------------------------

The 28 rats were randomly categorized into four groups (n=7), namely control, diabetic, Pioglitazone-treated and metformin-treated diabetic rats.

The first group of rats was the control group and did not receive any substance. The second (diabetic) group did not receive any treatment except for STZ and NA. The third group received 20 mg/kg/day of pioglitazone for diabetes treatment ([@B28]), and the final group received 100 mg/kg/day of metformin ([@B12]). Treatments were administered by orogastric gavage and continued for 4 weeks ([@B28]).

Rats were maintained in diabetic condition for 3 weeks (one sexual cycle) and then underwent treatment with metformin or pioglitazone.

Treatments with the two drugs lasted 4 weeks and for the next step, each of the 3 female rats were mated with 1 male rat and vaginal plug was observed the following morning (first day of pregnancy). Animals were anesthetized and sacrificed on the 4^th^ day of pregnancy, considered as the implantation day ([@B6]). The rat uteri were then removed, snap-frozen in liquid nitrogen and stored at -80°C for further analysis

Real time polymerase chain reaction
-----------------------------------

### RNA extraction

Total RNA was isolated from epithelial cells of endometrium using the RNX plus solution (Cinnagen, Iran) according to the manufacturer's instructions and as previously described. The purity and integrity of the extracted RNA were assessed by optical density measurements (260/280 nm ratios) and by visual observation of samples electrophoresed on agarose gels. For elimination of genomic DNA, RNA was treated with RNase-free DNase (Qiagen, Germany)

### cDNA synthesis

Complementary DNA (cDNA) synthesis was carried out by using a cDNA synthesis Kit (Yektatajhiz, Iran). Briefly, the synthesis mixture was prepared by adding 4 μl of 5 X first-strand buffer, 1 μl of dNTPs, 0.5 μl of RNasin and 1 μl of M-MLV. Approximately 1 μg of RNA and random hexamer primers were finally added to the mixture in a 20 μl reaction

Quantitative real-time polymerase chain reaction
------------------------------------------------

Specific primers for the rat β-actin (as an internal control, Accession number: NM_031144) and osteopontin (NM_012881.2) genes were designed with Genrunner software version 3.05 (Hastings Software, Hastings, NY, USA). All designed primers were checked against the the rat genome using BLAST to make sure they are not complementary with other regions of genome.

The sequences of the designed primers are as follow:

1.  F: 5´-AGGAGAAGGCGCATTACAG-3´

2.  R: 5´-GCTTTCATTGGAGTTGCTTG -3´

with an amplicon size of 160 bp and

1.  F: 5´-GCCTTCCTTCCTGGGTATG-3´

2.  R: 5´-AGGAGCCAGGGCAGTAATC-3´

with an amplicon size of 165 bp.

PCR was carried out by using the specific primers along with the Maxima™ SYBR Green/ROX qPCR Master MIX (Fermentas, Lithuaria) and run on an Applied Biosystems StepOnePlus instrument. The PCR cycling conditions were an initial denaturation step at 95˚C for 10 minutes, followed by 40 amplification cycles of denaturation at 95˚C for 10 seconds, annealing at 60˚C and 58.8˚C for β-actin and osteopontin genes respectively for 10 seconds, and extension at 72˚C for 10 seconds. All samples were measured in duplicate. The 2^-ΔΔCt^ method was utilized to quantify the relative levels of gene expression.

Statistical analyses
--------------------

Statistical analyses were performed using SPSS version 18.0 (SPSS Inc, Chicago, IL, USA). All data are expressed as mean ± standard error of mean (SEM) from at least in triplicate at two separate experiments. Differences between groups were analyzed using Analysis of Variance (ANOVA) with post hoc multiple comparisons. Statistical significance was defined as P\<0.05.

Results
=======

Figure 1 shows fasting plasma glucose concentrations in diabetic rat models (399.28 ± 84.61) and in those treated with metformin (103.28 ± 14.12) and pioglitazone (99.29 ± 6.70). There was a significant difference between the diabetic group and all other groups (P=0.0001).

The differential expression of the target gene was compared with the house keeping gene (β-actin) in all samples. As shown in Table 1 and Figure 2, the mean of *Opn* expression in the diabetic group (30.70 ± 11.65) was significantly different from the control group ([@B1]) (P=0.04) but no significant difference was observed between diabetic and metformin treated group (42.11 ± 19.07) (P=0.07). Therefore in diabetic group and diabetic treated with metformin group upregulation in expression of *Opn* gene were observed. Also, the diabetic treated with pioglitazone group (0.55 ± 0.22) showed no significant difference compared with the control group ([@B1]) (P=0.3).

Figure 3 shows the non-significant difference observed in *Opn* mRNA expression in metformin treated group (1.371 ± 0.621) compared to diabetic group ([@B1]) (P=0.62). On the other hand, there was a significant reduction in the expression of *Opn* in pioglitazone treated group (0.017 ± 0.007) compared with the diabetic group ([@B1]) (P=0.04).

![Fasting plasma glucose concentrations in diabetic rat models and in those treated with metformin and pioglitazone. \*; Significant difference between the diabetic group and other groups (P=0.0001), FBS; Fasting blood sugar, met; Metformin, and PI; Pioglitazone.](Int-J-Fertil-Steril-12-293-g01){#F1}

###### 

Mean level of Opn transcript expression in different groups

  ---------------------- ----------------------- -------------------------
                                                 
  Groups                 Specific (mean ± SEM)   Normalized (mean ± SEM)
                                                 
  Control                0.35                    1
  Sham                   0.29 ± 0.12             0.83 ± 0.35
  Diabetic               10.99 ± 4.17            30.70 ± 11.65
  Pioglitazone treated   0.19 ± 0.08             0.55 ± 0.22
  Metformin treated      15.08 ± 6.83            42.11 ± 19.07
                                                 
  ---------------------- ----------------------- -------------------------

![Fold change expression of *Opn* /β-actin gene relative to the control group based on real time polymerase chain reaction analysis in the rat endometrium. *Opn* transcript expression was significantly higher in the diabetic and diabetic+met groups in comparison with the control subjects (P=0.04). \*; P\<0.05, met; Metformin, and PI; Pioglitazone.](Int-J-Fertil-Steril-12-293-g02){#F2}
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Discussion
==========

This study was designed to investigate the effects of diabetes on *Opn* gene expression at the implantation stage after being treated with metformin and pioglitazone. Osteopontin transcript expression was significantly higher in the diabetic group in comparison with the control group. Furthermore, evidence for the ability of pioglitazone to downregulate *Opn* expression was shown. Given the high *Opn* expression and the possibility of increased adhesion of endometrial epithelial cells, the invasion of blastocyst may be affected and thus reduced. As pioglitazone significantly reverted the *Opn* expression in diabetic rats, it may be considered as a therapeutic compound to act against this molecular perturbation.

Receptivity of endometrium, mature blastocyst and dialogue between them are essential for the multifactorial nature of embryo implantation. The duration of this dialogue window is different among mammals, but should be present for a limited time for embryo reception ([@B5]).

Failure in the onset of pregnancy is widely due to inappropriate endometrial receptivity ([@B29]). Several endometrial growth factors, cytokines and adhesion molecules such as osteopontin cooperate in molecular pathways which are necessary for pregnancy ([@B30], [@B31]).

*Opn* transcript level increases at the implantation sites from day 5 to 8 of pregnancy in the mouse uterus. Therefore, *Opn* expression is thought to be essential for hatching and adhering the trophoblast to the endometrium ([@B5]).

In addition, at the protein expression level, *Opn* and β3 integrin positive cells were significantly higher on the 5th day of pregnancy. The presence of these two proteins were proposed as suitable markers for predicting the fate of ongoing implantation by the authors ([@B32]). *Opn* expression is also reported during the peri-implantation period, which is under control of progesterone in rabbit ([@B33]).

Young et al. ([@B34]) showed that in the proliferative phase of the menstrual cycle, *Opn* was not observed, however, its presence was observed during the secretory phase.

*Opn* expression has also been studied in normal endometrium during implantation in human ([@B32]), rat ([@B23]), mouse ([@B35]), sheep and pig ([@B36]). Here, we evaluated its expression in diabetic rats during the implantation window and observed significant overexpression when compared with the control group.

Diabetes mellitus in women could cause reduction of fertility, poor reproduction outcome and molecular abnormalities in ovary and endometrium ([@B37]). In diabetic mice models, the implantation outcome is shown to be lower than control mice ([@B14]).

Takemoto et al. ([@B38]) observed enhanced *Opn* expression levels in cultured rat aortic smooth muscle cells which were maintained in a medium with high glucose levels and suggested that it may be involved in the development of diabetic vascular complication.

Streptozotocin-induced diabetes mellitus in rats leads to the reduction of endometrial thickness while treating with pioglitazone and zinc improves the damages in the endometrium ([@B25]).

Up-regulation of *Opn* has been reported in renal tissue of diabetic rat models, which may implicate this molecule as a potential key pathophysiologic factor in diabetic nephropathy. Treatment with pioglitazone is thought to suppress *Opn* expression levels ([@B39]).

Consistently, we observed a significant reduction in the expression of *Opn* in the group treated with pioglitazone in comparison with the diabetic group. This indicates that pioglitazone has the ability to control the overexpression of *Opn* gene, which is probably in relation to the effect of pioglitazone on PPAR- γ (a regulator of gene expression). Further studies are nevertheless required to suggest administration of pioglitazone.

Another common drug for the treatment of diabetes is metformin, which causes an increase in intracellular magnesium concentration along with a lower blood glucose level in the uterus and ovary ([@B12]). Metformin seems to have positive effects on other organs such as the kidney where it significantly protects renal function in diabetic nephropathy ([@B40]). In this study, we observed no significant effect of metformin on *Opn* expression in the endometrium of diabetic rats.

Conclusion
==========

We conclude that due to the high expression of *Opn* and the possibility of increased adhesion of endometrial cells to each other, the invasion of blastocyst into uterine epithelium is likely reduced. Also, pioglitazone significantly down-regulates the expression *Opn* back to its normal levels in the female diabetic rats.
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